While pharmacologic therapies remain central to managing PsO and PsA, non-pharmacologic interventions also play a crucial ...
Delays in diagnosing and treating psoriatic arthritis—a common inflammatory disorder affecting around 200,000 people in the U ...
The findings highlight the potential benefits of newer biologics targeting IL-12, IL-23, and IL-17 while also raising ...
A new study explores gaps in how patients and physicians view psoriatic arthritis (PsA) and recommends ways for clinicians to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results